
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York - Thalidomide, once feared for its link to severe birthdefects, has shown success in a patient with malignant melanoma.